1. Benraad H, Drayer J, Hoefnagels W, Kloppenburg P, Benraad T (1978) Role of aldosterone in antihypertensive effect of spironolactone in essential hypertension. Clin Pharmacol Ther 24: 638
2. Collins RD, Weinberger MH, Dowdy AJ, Nokes GW, Gonzales CM, Luetscher JA (1970) Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension, relation to plasma renin activity. J Clin Invest 49: 1415
3. Davies DL, Beevers DG, Brown JJ, Cumming AM, Fraser R, Lever AF, Mason PA, Morton JJ, Robertson JIS, Titterington M, Tree M (1979) Aldosterone and its stimuli in normal and hypertensive man: are essential hypertension and primary hyperaldosteronism without tumour the same condition? J Endocrinol 81: 79
4. Fournier A, Lagrue G, Baulon A, Nakache JP, Kazandjian M, Legrand JC, Menard J (1972) Significance and prediction of spironolactone effectiveness in essential hypertension. In: Extrarenal activity of aldosterone and its antagonist. Excerpta Medica, Amsterdam, p 54
5. Genest J, Nowaczynski W, Kuchel O, Sasaki C (1972) Plasma progesterone levels and 18-hydroxydeoxyeorticosterone secretion rate in benign hypertension in humans. In: Genest J, Koiw M (eds) Hypertension 72. Springer, Berlin Heidelberg New York, p 293